Foretinib

CAT:
804-HY-10338-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Foretinib - image 1

Foretinib

  • Description:

    Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
  • Product Name Alternative:

    XL880; GSK1363089; GSK089; EXEL-2880
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H315, H319, H335
  • Target:

    C-Met/HGFR; VEGFR
  • Type:

    Reference compound
  • Related Pathways:

    Protein Tyrosine Kinase/RTK
  • Applications:

    Cancer-Kinase/protease
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/Foretinib.html
  • Concentration:

    10mM
  • Purity:

    99.59
  • Solubility:

    DMSO : 75 mg/mL (ultrasonic)
  • Smiles:

    O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=O
  • Molecular Formula:

    C34H34F2N4O6
  • Molecular Weight:

    632.65
  • Precautions:

    H302, H315, H319, H335
  • References & Citations:

    [1]Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69 (20), 8009-8016.|[2]Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011.|[3]Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res, 2010, 16 (13), 3507-3516.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Phase 2
  • Isoform:

    VEGFR1/Flt-1; VEGFR2/KDR/Flk-1
  • CAS Number:

    [849217-64-7]